What type of targeted drug does lapatinib belong to?

Lapatinib (Lapatinib) is a small molecule tyrosine kinase inhibitor and an oral targeted drug. It mainly targets two key receptor tyrosine kinases: HER2 (human epidermal growth factor receptor 2) and EGFR (epidermal growth factor receptor), thereby blocking the signal transduction pathways in tumor cells and inhibiting the proliferation and survival of tumor cells. Lapatinib's dual-target properties make it play an important role in the treatment of HER2-positive breast cancer.

HER2 is a protein that is overexpressed in some breast cancers, leading to abnormal cell proliferation and cancer progression. Lapatinib binds to the tyrosine kinase domain of HER2, inhibits its tyrosine kinase activity, blocks downstream signal transduction pathways, such as the PI3K/AKT and MAPK pathways, and ultimately inhibits tumor growth. In addition, lapatinib can also inhibit EGFR and further enhance the anti-tumor effect.

Unlike traditional monoclonal antibodies targeting HER2, lapatinib is an oral small molecule drug that can penetrate cell membranes and act on the tyrosine kinase domain in cells. This gives it certain advantages in the treatment of patients with brain metastases because it can cross the blood-brain barrier and produce therapeutic effects on brain lesions. In addition, lapatinib is often used in combination with other chemotherapy drugs to enhance efficacy and delay drug resistance.

In general, lapatinib, as a dual-target tyrosine kinase inhibitor, opens up a new way to treat HER2 positive breast cancer. Its convenience of oral administration and strong ability to penetrate the blood-brain barrier make it one of the important treatment options for patients with advanced and metastatic breast cancer. It also provides a useful reference and foundation for future targeted therapies.

Reference materials:https://www.drugs.com/